Big pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Merck should be concerned about the health and well-being of consumers with which it provides drugs to relieve various medical conditions. Unfortunately, the “big pharma” industry is only interest in one thing–making money at the expense of the people desperately seeking their assistance. Even physicians like to think that drug manufacturers are putting the interest of the public first and their financial interests last. However, Pfizer and its industry companions understand that remaining lucrative means providing drugs that only alleviate symptoms or cause addiction to their drugs.
Clinical Trials and Research Performed by Pharmaceutical Companies are Biased or Misleading
In the U.S. and European Union countries, all new drugs must undergo rigorous clinical trials before they can be approved and released for general use by that country’s regulatory committees. However, most research results are financed by the pharmaceutical company that makes the drug. Consequently, any significantly statistical results that can be skewed or distorted by professional statistician is likely to occur that supposedly show the “effectiveness” of the drug. An example of this biased reporting strategy would be a pharmaceutical company publishing data that reveals a new drug is better than an older, similar drug. However, the data fails to clearly describe that one group of subjects were given higher doses of the new drug while another group was given lower doses of the older drug.
Kanna as a Safe and Effective Alternative to Often Dangerous and Addictive Pharmaceuticals
Drug companies don’t want consumers to know about the rapidly growing interest in Kanna’s medicinal properties. In fact, scientists are currently conducting many clinically controlled research studies on Kanna’s alkaloids and phytochemicals that involve both animal and human subjects. Results of several of these studies indicate that Kanna appears to be just as effective at relieving depression, anxiety and other stress-related symptoms as antidepressants or addictive benzodiazepines.
In this study, Kanna was given to subjects in two doses–eight mg and 25 mg–once a day. Other subjects were given placebos once daily for 90 days. Results concluded that both doses of Kanna were well-tolerated, with subjects taking Kanna noting an “improved coping with stress and sleep”. This was a randomized, double-blind study, meaning subjects did not know what type of substance they were given at the beginning of the study.
The authors of this study state that “anxiety is characterized by hyper-responsivity to mild threats”. By using fMRI imaging scans on the brains of subjects who had taken Kanna, the authors noted that certain organelles in the brain involved in fear and anxiety–specifically the amygdala–appeared to react minimally to threats as a result of the anxiolytic (anxiety-reducing) properties of Kanna. In summarizing their study, researchers assert that “our results support the potential anxiety-reducing properties of Kanna and provides a foundation for exploring the clinical potential [of Kanna] for the treatment of depression and anxiety disorders”.
Sceletium (Kanna)—A review update
In this Journal of Ethnopharmacology article, the authors write that “sceletium are among the most commercially promising South African plants, with potential applications of raw material, extracts and isolated compounds spanning dietary supplement, natural medicine, veterinary and pharmaceutical uses”.
Cases described in this article include the story of a medical doctor who was suffering severe and debilitating depression exacerbated by suicidal ideation and weight loss. After the doctor began taking a 50 mg tablet of Sceletium each day, he reported a “sustained improvement in mood, with marked decrease in anxiety and insomnia”. After using Kanna for four months, the doctor discontinued the treatment and experienced no signs of withdrawal or other adverse side effects.
Another case involved a patient with a personality disorder and feelings of despondency, emptiness and pervasive sadness. Within 10 days of beginning a regimen of Kanna tablets, the patient reported that “her mood had lifted, she was more focused, more engaged, less anxious and not as socially distant”. According to the authors, the patient also described “feeling less inclined to over-indulge in alcohol”, which may give credence to other reports of traditional healers using Kanna to relieve withdrawal symptoms suffered by alcoholics trying to overcome their addiction.
Buy Kanna Wholesale Online and Find Relief from Anxiety and Depression
As more people are starting to realize the misleading information being forced on consumers by pharmaceutical companies that are only concerned about making money, the purchase of safe and effective medicinal plants such as Kanna will continue to gain in popularity and help millions of people find long-term relief from depression, anxiety, chronic fatigue and many other ailments.